Description
Presenter: Joshua Gray, Timothy Regan, Tommy Gunawan Overview. This webinar examines emerging pharmacological and non-pharmacological treatments for substance use disorders (SUD). Expert panelists will discuss genetically-informed pharmacological treatment development for alcohol use disorder and the use of real-world electronic health record (EHR) data to identify signals of treatment effectiveness. The presentation will also cover select digital health approaches to SUD assessment and treatment, including smartphone-based and artificial intelligence-enabled methods. Overall, the session emphasizes translational relevance, methodological innovation, and future directions for behavioral health. Objectives.
- Describe the role of genetically-informed strategies in the development of new pharmacological treatments for alcohol use disorder.
- Explain how real-world electronic health record (EHR) data can be leveraged to identify and evaluate signals of treatment effectiveness for substance use disorders.
- Identify emerging digital health approaches—including smartphone-based and AI-enabled methods—for the assessment and treatment of substance use
About the Presenter. Joshua Gray, PhD, is an Associate Professor of Medical and Clinical Psychology at the Uniformed Services University and a licensed clinical psychologist. His research applies large-scale genetic approaches to identify biological mechanisms of addiction and uncover opportunities for drug repurposing. He also conducts health services research to improve the identification and treatment of unhealthy alcohol use among military and civilian populations. Timothy Regan, PhD, is an Assistant Professor of Medical and Clinical Psychology at the Uniformed Services University and a licensed clinical psychologist. His research studies the biopsychosocial mechanisms influencing substance use. His work also examines the intersections between technology and addictive behaviors, such as testing novel digital behavioral health treatment approaches as well as conceptualizing problematic forms of technology use. Tommy Gunawan is a scientist whose work focuses on the neuropsychopharmacology of psychotropic drugs, and the etiology of substance use disorders and psychiatric comorbidities. His research focuses on how environmental, psychosocial, pharmacological, and genetic factors interact to modulate drug effects and risk of psychiatric disorders, and identify markers that modulate treatment response.
CE Information
1 hour of CE
Cost
FREE for MEMBERS $40.00 for Non-Members
If you have an account, please log in first:
SCP Member?
Apply Coupon to get this webinar for free.